Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1994 Sep;70(3):409–414. doi: 10.1038/bjc.1994.319

Effects of a new antioestrogen, idoxifene, on cisplatin- and doxorubicin-sensitive and -resistant human ovarian carcinoma cell lines.

S Y Sharp 1, M G Rowlands 1, M Jarman 1, L R Kelland 1
PMCID: PMC2033360  PMID: 8080723

Abstract

Pyrrolidino-4-iodotamoxifen (idoxifene) is a new non-steroidal antioestrogen currently undergoing phase I clinical evaluation. Using idoxifene and tamoxifen and two additional analogues of tamoxifen (3-hydroxytamoxifen and 4-iodotamoxifen) and the imidazole-based calmodulin inhibitor, calmidazolium, a strong positive correlation (r2 > 0.95) was observed between cytotoxicity and inhibition of calmodulin-dependent cyclic AMP phosphodiesterase (e.g. mean IC50 across four human ovarian carcinoma cell lines of 4.5 microM for idoxifene and 6.3 microM for tamoxifen). Using two parent human ovarian carcinoma cell lines (41M and CH1; both oestrogen receptor negative) in which acquired resistance to doxorubicin or cisplatin has been generated, we have determined the ability of idoxifene to overcome resistance in these lines. At a non-toxic concentration of 2 microM, idoxifene appeared at least as effective as the clinically used multidrug resistance modifiers verapamil and tamoxifen in overcoming doxorubicin resistance in two acquired resistant cell lines shown to overexpress the P-170 efflux glycoprotein. Non-cross-resistance between cisplatin and idoxifene was observed in two acquired resistant cell lines possessing contrasting mechanisms of resistance to cisplatin (41McisR6 reduced drug transport and CH1cisR6 resistance mediated at the level of DNA). In one of four cell lines (CH1), synergism between idoxifene and cisplatin was observed by median effect analysis. However, with the 41M and its 6-fold cisplatin-resistant variant, antagonism was observed. These observations made by median effect analysis appeared to be unrelated to platinum uptake or removal of platinum-induced DNA interstrand cross-links. These in vitro data suggest that idoxifene may be usefully combined with doxorubicin in the clinical setting, but caution should be exercised in combining it with cisplatin in the treatment of certain tumours.

Full text

PDF
409

Images in this article

412Figure 3
on p.412

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bruning P. F. Droloxifene, a new anti-oestrogen in postmenopausal advanced breast cancer: preliminary results of a double-blind dose-finding phase II trial. Eur J Cancer. 1992;28A(8-9):1404–1407. doi: 10.1016/0959-8049(92)90530-f. [DOI] [PubMed] [Google Scholar]
  2. Chander S. K., McCague R., Luqmani Y., Newton C., Dowsett M., Jarman M., Coombes R. C. Pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen, new analogues of the antiestrogen tamoxifen for the treatment of breast cancer. Cancer Res. 1991 Nov 1;51(21):5851–5858. [PubMed] [Google Scholar]
  3. Chou T. C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27–55. doi: 10.1016/0065-2571(84)90007-4. [DOI] [PubMed] [Google Scholar]
  4. Cole S. P., Bhardwaj G., Gerlach J. H., Mackie J. E., Grant C. E., Almquist K. C., Stewart A. J., Kurz E. U., Duncan A. M., Deeley R. G. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science. 1992 Dec 4;258(5088):1650–1654. doi: 10.1126/science.1360704. [DOI] [PubMed] [Google Scholar]
  5. Foster A. B., Jarman M., Leung O. T., McCague R., Leclercq G., Devleeschouwer N. Hydroxy derivatives of tamoxifen. J Med Chem. 1985 Oct;28(10):1491–1497. doi: 10.1021/jm00148a020. [DOI] [PubMed] [Google Scholar]
  6. Hait W. N. Targeting calmodulin for the development of novel cancer chemotherapeutic agents. Anticancer Drug Des. 1987 Oct;2(2):139–149. [PubMed] [Google Scholar]
  7. Hills C. A., Kelland L. R., Abel G., Siracky J., Wilson A. P., Harrap K. R. Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes. Br J Cancer. 1989 Apr;59(4):527–534. doi: 10.1038/bjc.1989.108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Kartner N., Riordan J. R., Ling V. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science. 1983 Sep 23;221(4617):1285–1288. doi: 10.1126/science.6137059. [DOI] [PubMed] [Google Scholar]
  9. Kelland L. R., Mistry P., Abel G., Loh S. Y., O'Neill C. F., Murrer B. A., Harrap K. R. Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates. Cancer Res. 1992 Jul 15;52(14):3857–3864. [PubMed] [Google Scholar]
  10. Kelland L. R., Murrer B. A., Abel G., Giandomenico C. M., Mistry P., Harrap K. R. Ammine/amine platinum(IV) dicarboxylates: a novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res. 1992 Feb 15;52(4):822–828. [PubMed] [Google Scholar]
  11. Kikuchi Y., Iwano I., Miyauchi M., Sasa H., Nagata I., Kuki E. Restorative effects of calmodulin antagonists on reduced cisplatin uptake by cisplatin-resistant human ovarian cancer cells. Gynecol Oncol. 1990 Nov;39(2):199–203. doi: 10.1016/0090-8258(90)90432-k. [DOI] [PubMed] [Google Scholar]
  12. Lam H. Y. Tamoxifen is a calmodulin antagonist in the activation of cAMP phosphodiesterase. Biochem Biophys Res Commun. 1984 Jan 13;118(1):27–32. doi: 10.1016/0006-291x(84)91062-3. [DOI] [PubMed] [Google Scholar]
  13. Loh S. Y., Mistry P., Kelland L. R., Abel G., Harrap K. R. Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes. Br J Cancer. 1992 Dec;66(6):1109–1115. doi: 10.1038/bjc.1992.419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. McCague R., Leclercq G., Legros N., Goodman J., Blackburn G. M., Jarman M., Foster A. B. Derivatives of tamoxifen. Dependence of antiestrogenicity on the 4-substituent. J Med Chem. 1989 Dec;32(12):2527–2533. doi: 10.1021/jm00132a006. [DOI] [PubMed] [Google Scholar]
  15. McClay E. F., Albright K. D., Jones J. A., Christen R. D., Howell S. B. Tamoxifen modulation of cisplatin cytotoxicity in human malignancies. Int J Cancer. 1993 Dec 2;55(6):1018–1022. doi: 10.1002/ijc.2910550623. [DOI] [PubMed] [Google Scholar]
  16. McClay E. F., Albright K. D., Jones J. A., Christen R. D., Howell S. B. Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells. Cancer Res. 1993 Apr 1;53(7):1571–1576. [PubMed] [Google Scholar]
  17. McClay E. F., Albright K. D., Jones J. A., Eastman A., Christen R., Howell S. B. Modulation of cisplatin resistance in human malignant melanoma cells. Cancer Res. 1992 Dec 15;52(24):6790–6796. [PubMed] [Google Scholar]
  18. Means A. R. Molecular mechanisms of action of calmodulin. Recent Prog Horm Res. 1988;44:223–262. doi: 10.1016/b978-0-12-571144-9.50012-0. [DOI] [PubMed] [Google Scholar]
  19. O'Brian C. A., Liskamp R. M., Solomon D. H., Weinstein I. B. Inhibition of protein kinase C by tamoxifen. Cancer Res. 1985 Jun;45(6):2462–2465. [PubMed] [Google Scholar]
  20. Perez R. P., Handel L. M., Hamilton T. C. Potentiation of cisplatin cytotoxicity in human ovarian carcinoma cell lines by trifluoperazine, a calmodulin inhibitor. Gynecol Oncol. 1992 Jul;46(1):82–87. doi: 10.1016/0090-8258(92)90201-s. [DOI] [PubMed] [Google Scholar]
  21. Perez R. P., Perez K. M., Handel L. M., Hamilton T. C. In vitro interactions between platinum analogues in human ovarian-carcinoma cell lines. Cancer Chemother Pharmacol. 1992;29(6):430–434. doi: 10.1007/BF00684842. [DOI] [PubMed] [Google Scholar]
  22. Ramu A., Glaubiger D., Fuks Z. Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by tamoxifen and other triparanol analogues. Cancer Res. 1984 Oct;44(10):4392–4395. [PubMed] [Google Scholar]
  23. Roberts J. J., Friedlos F. Quantitative estimation of cisplatin-induced DNA interstrand cross-links and their repair in mammalian cells: relationship to toxicity. Pharmacol Ther. 1987;34(2):215–246. doi: 10.1016/0163-7258(87)90012-x. [DOI] [PubMed] [Google Scholar]
  24. Scambia G., Ranelletti F. O., Benedetti Panici P., Piantelli M., De Vincenzo R., Bonanno G., Ferrandina G., Isola G., Mancuso S. Synergistic antiproliferative activity of tamoxifen and cisplatin on primary ovarian tumours. Eur J Cancer. 1992;28A(11):1885–1889. doi: 10.1016/0959-8049(92)90029-2. [DOI] [PubMed] [Google Scholar]
  25. Towbin H., Staehelin T., Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350–4354. doi: 10.1073/pnas.76.9.4350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Twentyman P. R., Fox N. E., Wright K. A., Bleehen N. M. Derivation and preliminary characterisation of adriamycin resistant lines of human lung cancer cells. Br J Cancer. 1986 Apr;53(4):529–537. doi: 10.1038/bjc.1986.83. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES